CORAL GABLES, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst will present at the 43rd Annual J.P. Morgan Healthcare Conference taking place January 13-16, 2025 in San Francisco, CA. 43rd Annual J.P ...

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market engagement and confidence [1][2] Zacks Style Scores - Zacks Style Scores are indicators that rate stocks based on value, growth, and momentum methodologies, helping investors identify stocks likely to outperform the market in the next 30 days [3][4] - Each stock is rated from A to F, with A indicating the highest potential for outperformance [4] Categories of Style Scores - **Value Score**: Focuses on identifying undervalued stocks using ratios like P/E and Price/Sales [5] - **Growth Score**: Evaluates a company's financial health and future growth potential through earnings and sales projections [6] - **Momentum Score**: Assesses trends in stock prices and earnings estimates to identify favorable investment opportunities [7] - **VGM Score**: Combines all three Style Scores to highlight stocks with attractive value, growth forecasts, and momentum [8] Zacks Rank and Earnings Estimates - The Zacks Rank is a proprietary model that uses earnings estimate revisions to guide investors in building successful portfolios [9] - Stocks rated 1 (Strong Buy) have historically produced an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [10] - There are over 800 stocks rated 1 or 2, which can be overwhelming for investors [11] Investment Strategy - To maximize returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [12] - The direction of earnings estimate revisions is crucial; stocks with lower ranks but high Style Scores may still face price declines [13] Company Spotlight: Catalyst Pharmaceuticals - Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on therapies for rare diseases [14] - Currently rated 3 (Hold) with a VGM Score of A and a Value Style Score of B, indicating attractive valuation metrics [15] - The company has seen upward revisions in earnings estimates, with a Zacks Consensus Estimate of $2 per share for fiscal 2024 [15] - With a solid Zacks Rank and strong Style Scores, Catalyst Pharmaceuticals is recommended for investors' consideration [16]

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style ...

CORAL GABLES, Fla., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), today announced it ranked number 452 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30th year. The 2024 Deloitte Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2020 to 2023, for which Cata ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? The Z ...

Core Insights - Catalyst Pharmaceuticals has been recognized as one of the Best Places to Work in 2025 by BioSpace, highlighting its desirability in the life sciences community [1][2] - The recognition is based on evaluations of company culture, career growth opportunities, leadership, and innovation, with votes from over 3,000 life sciences professionals [2] Company Overview - Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, with a commitment to improving patient care [3] - The company has a strong U.S. presence and aims to expand its global footprint through strategic partnerships [3] - Catalyst was also recognized on the Forbes 2024 list as one of America's most successful small-cap companies [3]

Core Insights - Catalyst Pharmaceuticals (CPRX) reported adjusted earnings of 57 cents per share for Q3 2024, exceeding the Zacks Consensus Estimate of 49 cents and recovering from an adjusted loss of 24 cents in the same quarter last year [1] - Total revenues reached $128.7 million, reflecting a year-over-year growth of 25.3% and surpassing the Zacks Consensus Estimate of $123 million [1] Revenue Breakdown - The primary revenue source was Firdapse, which generated sales of $79.3 million, up 19.7% year over year, and exceeded the Zacks Consensus Estimate of $77.6 million [4] - Fycompa, acquired in 2023, generated net product revenues of $32.1 million, which was below the Zacks Consensus Estimate of $34.3 million and marked an 11.9% decline year over year [5] - Agamree, launched in March 2024, contributed $15 million in revenues, a 72% sequential increase, surpassing the Zacks Consensus Estimate of $11 million [8] Financial Guidance - Catalyst raised its 2024 total revenue guidance to a range of $475-$485 million from the previous $455-$475 million, driven by growth in Firdapse, Fycompa, and Agamree [10] - Firdapse revenue projections were adjusted to $300-$310 million, Fycompa remains at $130-$135 million, and Agamree is now expected to generate $40-$45 million [11] Cost Management - Research and development expenses were significantly reduced to $3.3 million, down 96.1% year over year, due to a one-time expense in the previous year [8] - Selling, general, and administrative expenses increased to $45.9 million, up 36.7% from the previous year, primarily due to the launch of Agamree and related marketing activities [9] Stock Performance - Year-to-date, CPRX shares have increased by 35.1%, contrasting with a 3.6% decline in the industry [6]

Financial Data and Key Metrics Changes - Total revenues for Q3 2024 were $128.7 million, a 25.3% increase year-over-year from $102.7 million in Q3 2023 [6][32] - Net product revenues for FIRDAPSE were $79.3 million, representing a 19.7% increase compared to $66.2 million in Q3 2023 [32][38] - Net revenues for FYCOMPA were $32.1 million, an 11.9% decrease from $36.4 million in Q3 2023 due to increased gross to net deductions [10][33] - Net revenues for AGAMREE were $15 million, reflecting strong commercial launch performance [34] Business Line Data and Key Metrics Changes - FIRDAPSE's performance was driven by new patient enrollments and a low annual discontinuation rate below the forecast of 20% [21][22] - AGAMREE's net sales of $15 million were driven by its expanding adoption, with 84% of top DMD centers prescribing it [25][27] - FYCOMPA's steady demand resulted in net revenues of $32.1 million, maintaining its position in the market [28] Market Data and Key Metrics Changes - The company updated its full year 2024 total revenue guidance to between $475 million and $485 million, reflecting strong performance across its product lines [7][41] - AGAMREE's full year 2024 net revenue guidance was raised to between $40 million and $45 million due to promising demand trends [27] Company Strategy and Development Direction - The company is focused on operational excellence, portfolio diversification, and global expansion to capitalize on emerging opportunities [18][49] - Strategic initiatives include evaluating promising opportunities in the rare disease space and expanding its rare disease portfolio through alliances [16][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resilience of the business and the strategies driving long-term growth, emphasizing the importance of innovation and operational excellence [49] - The company is optimistic about AGAMREE's market potential and its ability to drive meaningful long-term growth [9] Other Important Information - The company ended Q3 2024 with cash and cash equivalents of $442.3 million, a significant increase from $137.6 million at the end of 2023 [46][47] - Research and development expenses were significantly lower at $3.3 million compared to $83.7 million in Q3 2023, which included a large charge for in-process R&D [37][42] Q&A Session Summary Question: What are the expectations for FIRDAPSE's commercialization in other regions like China? - Management is exploring opportunities in China and will provide updates as they become clearer [53] Question: What drove the gross to net adjustment for FYCOMPA? - The increase in fees with distributors and government agencies compared to previous arrangements was noted as a key factor [54] Question: What is the source of uptake for FIRDAPSE and the status of the patient pipeline? - The small cell lung cancer LEMS patient mix is around 20% to 25%, and the pipeline remains stable with over 500 patients [58][59] Question: How does AGAMREE compare to EMFLAZA in terms of peak sales potential? - Management believes AGAMREE has the potential to outperform EMFLAZA, although it is launching in a competitive market [60][61] Question: What are the synergies in the commercial strategies for FIRDAPSE and AGAMREE? - The sales approach differs, with FIRDAPSE focusing on patient testing and diagnosis, while AGAMREE targets a concentrated group of prescribers [66] Question: What is the target product profile for the SUMMIT study? - The study aims to gather long-term data on AGAMREE's effects on bone health and muscle strength, with a focus on high-quality data collection [70][72]

Have you been paying attention to shares of Catalyst Pharmaceutical (CPRX) ? Shares have been on the move with the stock up 13.7% over the past month. The stock hit a new 52-week high of $23.12 in the previous session. Catalyst Pharmaceutical has gained 35.1% since the start of the year compared to the 3.2% move for the Zacks Medical sector and the -2.8% return for the Zacks Medical - Drugs industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't m ...

Core Insights - Catalyst Pharmaceutical (CPRX) reported a revenue of $128.7 million for the quarter ended September 2024, reflecting a year-over-year increase of 25.3% [1] - The earnings per share (EPS) for the quarter was $0.57, a significant improvement from -$0.24 in the same quarter last year [1] - The reported revenue exceeded the Zacks Consensus Estimate of $122.97 million by 4.65%, and the EPS surpassed the consensus estimate of $0.49 by 16.33% [1] Revenue Breakdown - Product revenue from FIRDAPSE was $79.30 million, exceeding the average estimate of $77.60 million from five analysts [3] - Total product revenue was $126.42 million, compared to the five-analyst average estimate of $122.93 million [3] - Product revenue from AGAMREE reached $15.05 million, surpassing the average estimate of $10.99 million [3] - Product revenue from FYCOMPA was $32.08 million, slightly below the average estimate of $34.34 million [3] Stock Performance - Catalyst's shares have returned +9.4% over the past month, outperforming the Zacks S&P 500 composite, which saw a change of +0.7% [4] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [4]